Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03282435
NCT03282435UnknownPhase 1

Treatment of Non-small Cell Lung Cancer With CIK Cells Blocked by PD-1 Antibody

Dalian University0 sites30 target enrollmentStarted: January 1, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Sponsor
Enrollment
30
Primary Endpoint
progression-free survival
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

to evaluate the prognosis of non-small cell lung carcinoma patients under CIK cellular treatment with PD-1 blocking on top of the standard therapy

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Factorial
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
40 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •non-small cell lung cancer;
  • •more than 50% tumor tissues positive with PD-L1;
  • •EGFR and ALK wild type
  • •no other tumors

Exclusion Criteria

  • •with systematic diseases shortening survival

Outcomes

Primary Outcomes

progression-free survival

Time Frame: 5 years

metastasis-free survival

Time Frame: 5 years

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Dalian University
Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials

Unknown
Not Applicable
The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine KinaseNon-Small-Cell Lung Cancer
NCT02755337Dr. Soetomo General Hospital70
Completed
Not Applicable
Non-small Cell Lung Cancer and Quality of LifeNon Small Cell Lung Cancer
NCT00818402University of Turku130
Completed
Phase 4
Chemotherapy Combined With CIK Treating Colon CancerColorectal CancerCytokine-induced Killer CellsPostoperative ComplicationsSurvival
NCT03084809China Meitan General Hospital46
Completed
Not Applicable
tritional Assessment in Non-small Cell lung cancer patientslungcancerNon Small Cell Lung Cancer10038666
NL-OMON50451Antoni van Leeuwenhoek Ziekenhuis100
Recruiting
Phase 1
Pentixafor Positron Emission Tomography Scan: A New Imaging Test for Staging in Non-small Cell Lung Canceron-small cell lung cancerCancer - Lung - Non small cellNon-small cell lung cancer
ACTRN12615001265561Oceanic Molecular Imaging30